293 related articles for article (PubMed ID: 16350417)
1. Generation of HPV pseudovirions using transfection and their use in neutralization assays.
Buck CB; Pastrana DV; Lowy DR; Schiller JT
Methods Mol Med; 2005; 119():445-62. PubMed ID: 16350417
[TBL] [Abstract][Full Text] [Related]
2. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18.
Pastrana DV; Buck CB; Pang YY; Thompson CD; Castle PE; FitzGerald PC; Krüger Kjaer S; Lowy DR; Schiller JT
Virology; 2004 Apr; 321(2):205-16. PubMed ID: 15051381
[TBL] [Abstract][Full Text] [Related]
3. Infectious human papillomavirus type 18 pseudovirions.
Stauffer Y; Raj K; Masternak K; Beard P
J Mol Biol; 1998 Oct; 283(3):529-36. PubMed ID: 9784363
[TBL] [Abstract][Full Text] [Related]
4. [Establishment and application of human papillomavirus type 16 pseudovirions neutralization assay].
Lu WX; Cheng T; Li SW; Pan HR; Shen WT; Chen YX; Zhang T; Zheng Z; Zhang J; Xia NS
Sheng Wu Gong Cheng Xue Bao; 2006 Nov; 22(6):990-5. PubMed ID: 17168325
[TBL] [Abstract][Full Text] [Related]
5. Generation and applications of HPV pseudovirions using vaccinia virus.
Sapp M; Selinka HC
Methods Mol Med; 2005; 119():463-82. PubMed ID: 16350418
[TBL] [Abstract][Full Text] [Related]
6. BPV1 E2 protein enhances packaging of full-length plasmid DNA in BPV1 pseudovirions.
Zhao KN; Hengst K; Liu WJ; Liu YH; Liu XS; McMillan NA; Frazer IH
Virology; 2000 Jul; 272(2):382-93. PubMed ID: 10873782
[TBL] [Abstract][Full Text] [Related]
7. Papillomavirus virus-like particles as vehicles for the delivery of epitopes or genes.
Xu YF; Zhang YQ; Xu XM; Song GX
Arch Virol; 2006 Nov; 151(11):2133-48. PubMed ID: 16791442
[TBL] [Abstract][Full Text] [Related]
8. DNA packaging by L1 and L2 capsid proteins of bovine papillomavirus type 1.
Zhao KN; Sun XY; Frazer IH; Zhou J
Virology; 1998 Apr; 243(2):482-91. PubMed ID: 9568045
[TBL] [Abstract][Full Text] [Related]
9. A comparative study of two different assay kits for the detection of secreted alkaline phosphatase in HPV antibody neutralization assays.
Kemp TJ; Matsui K; Shelton G; Safaeian M; Pinto LA
Hum Vaccin Immunother; 2015; 11(2):337-46. PubMed ID: 25695397
[TBL] [Abstract][Full Text] [Related]
10. Neutralization of human papillomavirus (HPV) pseudovirions: a novel and efficient approach to detect and characterize HPV neutralizing antibodies.
Yeager MD; Aste-Amezaga M; Brown DR; Martin MM; Shah MJ; Cook JC; Christensen ND; Ackerson C; Lowe RS; Smith JF; Keller P; Jansen KU
Virology; 2000 Dec; 278(2):570-7. PubMed ID: 11118379
[TBL] [Abstract][Full Text] [Related]
11. Nuclear location of minor capsid protein L2 is required for expression of a reporter plasmid packaged in HPV51 pseudovirions.
Kondo K; Ishii Y; Mori S; Shimabukuro S; Yoshikawa H; Kanda T
Virology; 2009 Nov; 394(2):259-65. PubMed ID: 19766281
[TBL] [Abstract][Full Text] [Related]
12. Generation and analysis of infectious virus-like particles of uukuniemi virus (bunyaviridae): a useful system for studying bunyaviral packaging and budding.
Overby AK; Popov V; Neve EP; Pettersson RF
J Virol; 2006 Nov; 80(21):10428-35. PubMed ID: 16928751
[TBL] [Abstract][Full Text] [Related]
13. Efficient intracellular assembly of papillomaviral vectors.
Buck CB; Pastrana DV; Lowy DR; Schiller JT
J Virol; 2004 Jan; 78(2):751-7. PubMed ID: 14694107
[TBL] [Abstract][Full Text] [Related]
14. Production of Human papillomavirus pseudovirions in plants and their use in pseudovirion-based neutralisation assays in mammalian cells.
Lamprecht RL; Kennedy P; Huddy SM; Bethke S; Hendrikse M; Hitzeroth II; Rybicki EP
Sci Rep; 2016 Feb; 6():20431. PubMed ID: 26853456
[TBL] [Abstract][Full Text] [Related]
15. Production of Furin-Cleaved Papillomavirus Pseudovirions and Their Use for In Vitro Neutralization Assays of L1- or L2-Specific Antibodies.
Wang JW; Matsui K; Pan Y; Kwak K; Peng S; Kemp T; Pinto L; Roden RB
Curr Protoc Microbiol; 2015 Aug; 38():14B.5.1-26. PubMed ID: 26237105
[TBL] [Abstract][Full Text] [Related]
16. Generation and neutralization of pseudovirions of human papillomavirus type 33.
Unckell F; Streeck RE; Sapp M
J Virol; 1997 Apr; 71(4):2934-9. PubMed ID: 9060652
[TBL] [Abstract][Full Text] [Related]
17. Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes.
Kondo K; Ochi H; Matsumoto T; Yoshikawa H; Kanda T
J Med Virol; 2008 May; 80(5):841-6. PubMed ID: 18360909
[TBL] [Abstract][Full Text] [Related]
18. A Cell-Free Assembly System for Generating Infectious Human Papillomavirus 16 Capsids Implicates a Size Discrimination Mechanism for Preferential Viral Genome Packaging.
Cerqueira C; Pang YY; Day PM; Thompson CD; Buck CB; Lowy DR; Schiller JT
J Virol; 2016 Jan; 90(2):1096-107. PubMed ID: 26559838
[TBL] [Abstract][Full Text] [Related]
19. Maturation of papillomavirus capsids.
Buck CB; Thompson CD; Pang YY; Lowy DR; Schiller JT
J Virol; 2005 Mar; 79(5):2839-46. PubMed ID: 15709003
[TBL] [Abstract][Full Text] [Related]
20. Assembly of human papillomavirus type 16 pseudovirions in Saccharomyces cerevisiae.
Rossi JL; Gissmann L; Jansen K; Müller M
Hum Gene Ther; 2000 May; 11(8):1165-76. PubMed ID: 10834618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
